REDUCE EXPOSURE: Enter at 25% of full target now (no more), or wait for confirmation above 172.47 and enter at 25-35% with stop at 10 EMA ~154

• One quarter of inflection (Q2 operating income negative $141M) does not justify 89x forward earnings; Q1 2026 showed $1.95B operating loss and $4.28B net loss just three months ago
• Stock-based compensation running at $831M per quarter is a continuous share creation mechanism not fully priced by the market
• Capex rose from $2.85B to $19.24B year-over-year (6x increase), compressing the analyst's claimed 5-year capex runway if burn rate continues upward
• Free cash flow of negative $16.8B with Starship/Starlink execution required for thesis; Polymarket shows only 30% probability of full reusability before 2027
• Three-session unconfirmed breakout with RSI approaching 70 and price below both 50-day and 200-day moving averages contradicts 'fresh uptrend' narrative
• Prior 52% drawdown after similar technical pattern demonstrates pattern failure risk; 89x multiple has no cushion for multiple compression in risk-off scenarios
• Tesla-SpaceX merger optionality fading (14% probability), not building; sub-5 Starship launch probability at 41% shows rising market pessimism
• 14% stop on 50-65% position equals 7-9% portfolio equity risk from single trade with structurally weak support levels

→ vs aggressive: One quarter of inflection does not justify 89x forward earnings; Q1 2026 showed $1.95B operating loss and $4.28B net loss just three months ago

→ vs aggressive: Stock-based compensation running at $831M per quarter is a continuous share creation mechanism not fully priced by the market

→ vs aggressive: Capex rose from $2.85B to $19.24B year-over-year (6x increase), compressing the analyst's claimed 5-year capex runway if burn rate continues upward

→ vs aggressive: Polymarket data shows rising pessimism: full reusability at only 30%, sub-5 Starship launches probability at 41%, Tesla-SpaceX merger fading at 14%

→ vs aggressive: Price below both 50-day and 200-day moving averages contradicts 'fresh uptrend' narrative; RSI approaching 70 signals overbought conditions

→ vs aggressive: Prior 52% drawdown after similar technical pattern demonstrates pattern failure risk; 89x multiple has no cushion for multiple compression

→ vs aggressive: Confirmation level at 172.47 is only 5.8% above proposed entry—if willing to wait for confirmation, wait and enter with tighter stop

→ vs aggressive: 14% stop on 50-65% position equals 7-9% portfolio equity risk from single trade with structurally weak support levels

Enter at 25-30% overweight at $163 with stop at $144; scale to 50-60% on confirmation above $172.47; max 70% overweight; exit if Polymarket reusability below 20% or Q3 misses Q2 trajectory

• Q2 EBITDA inflection from negative $1.16B to positive $2.96B is significant, but 89x forward earnings remains vulnerable to one bad quarter
• Free cash flow of negative $16.8B with capex accelerating 6.7x year-over-year creates runway risk if burn rate doesn't stabilize
• Aggressive analyst conflates having a thesis with valuation not mattering; conservative analyst treats valuation as disqualifier rather than sizing input
• Breakout pattern shares signatures with June peak (sharp run-up, high volume, RSI overbought, compressed volatility), suggesting 30-40% failure probability
• ATR compressed from 16 to 7 before breakout; double average volume on breakout day indicates institutional accumulation
• SBC dilution of $831M per quarter equals ~1.5% annualized relative to $2.26T market cap
• Waiting for $172.47 confirmation costs 5.8% upside on 60-70% probability continuation path; stop at 144 limits downside to 11.7%
• Conservative analyst's stop at $154 (tight) vs aggressive at $140 (wide); neutral stop at $144 sits below 200-SMA at $144.11
• Narrow market leadership and dovish Fed repricing have mixed historical track records; should not be treated as deterministic
• Q3 and Q4 confirmation would collapse the 89x multiple; failure would re-anchor valuation downward rapidly

→ vs aggressive: Calling negative $16.8B FCF 'a thesis not a problem' is language that gets written up in post-mortems; capex accelerating 6.7x in 12 months makes five-year runway calculation unreliable if burn continues increasing

→ vs aggressive: ATR compressing from 16 to 7 is a volatility regime signature but both current and June peaks share critical pattern: sharp run-up, high volume, RSI approaching overbought after compressed volatility; base rate on that pattern failing is not low

→ vs aggressive: '89x is an anchor trap' is rhetoric not analysis; at 89x forward earnings, one bad quarter causes rapid multiple compression; execution risk is real regardless of thesis quality

→ vs aggressive: Mixed sentiment argument is weakest part of case; low sentiment at high price can signal distribution, not just bullish 'marginal buyer hasn't shown up'; choosing bullish interpretation is selection bias

→ vs conservative: Valuation as disqualifier is wrong framework; should be sizing input; if Q3/Q4 confirm, 89x multiple collapses rapidly, making absolute valuation less relevant than risk-adjusted return

→ vs conservative: Wait for $172.47 confirmation has logic problem; if breakout has 65% continuation probability, waiting costs 5.8% upside on that path while conservative analyst hasn't justified why failure probability is high enough to warrant wait

→ vs conservative: Narrow leadership sell signal has mixed historical track record; sometimes resolves with drawdowns, sometimes leadership continues another 30-50% before rotation; applying late-cycle logic to growth name with unique balance sheet and catalyst calendar is wrong framework

→ vs conservative: SBC dilution magnitude is small relative to $2.26T market cap at ~1.5% annualized; treating it like original IPO dilution overstates the problem